Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents.

Nicolatou-Galitis O, Papadopoulou E, Vardas E, Kouri M, Galiti D, Galitis E, Alexiou KE, Tsiklakis K, Ardavanis A, Razis E, Athanasiadis I, Droufakou S, Psyrri A, Karamouzis MV, Linardou H, Daliani D, Tzanninis D, Sachanas S, Laschos K, Kyrtsonis MC, Antoniou F, Laskarakis A, Giassas S, Nikolaidi A, Rigakos G, Ntokou A, Migliorati CA, Ripamonti CI.

Oral Dis. 2020 Feb 3. doi: 10.1111/odi.13294. [Epub ahead of print]

PMID:
32011077
2.

Explorative investigation of the anti-glycative effect of a rapeseed by-product extract.

Navarro M, de Falco B, Morales FJ, Daliani D, Fiore A.

Food Funct. 2018 Nov 14;9(11):5674-5681. doi: 10.1039/c8fo01408f.

PMID:
30306992
3.

Sexual dysfunction in testicular cancer patients subjected to post-chemotherapy retroperitoneal lymph node dissection: a focus beyond ejaculation disorders.

Dimitropoulos K, Karatzas A, Papandreou C, Daliani D, Zachos I, Pisters LL, Tzortzis V.

Andrologia. 2016 May;48(4):425-30. doi: 10.1111/and.12462. Epub 2015 Aug 13.

PMID:
26268684
4.

Simple and reliable HPLC method for the monitoring of methotrexate in osteosarcoma patients.

Begas E, Papandreou C, Tsakalof A, Daliani D, Papatsibas G, Asprodini E.

J Chromatogr Sci. 2014 Aug;52(7):590-5. doi: 10.1093/chromsci/bmt081. Epub 2013 Jun 25.

PMID:
23800772
5.

Revisiting bleomycin from pathophysiology to safe clinical use.

Froudarakis M, Hatzimichael E, Kyriazopoulou L, Lagos K, Pappas P, Tzakos AG, Karavasilis V, Daliani D, Papandreou C, Briasoulis E.

Crit Rev Oncol Hematol. 2013 Jul;87(1):90-100. doi: 10.1016/j.critrevonc.2012.12.003. Epub 2013 Jan 9. Review.

PMID:
23312772
6.

Expression of neutral endopeptidase, endothelin-1, and nuclear factor kappa B in prostate cancer: interrelations and associations with prostate-specific antigen recurrence after radical prostatectomy.

Vlachostergios PJ, Karasavvidou F, Kakkas G, Moutzouris G, Patrikidou A, Voutsadakis IA, Daliani DD, Zintzaras E, Melekos MD, Papandreou CN.

Prostate Cancer. 2012;2012:452795. doi: 10.1155/2012/452795. Epub 2012 May 15.

7.

Basic Concepts in Metastatic Cardiac Disease.

Vlachostergios PJ, Daliani DD, Papandreou CN.

Cardiol Res. 2012 Apr;3(2):47-48. doi: 10.4021/cr155w. Epub 2012 Mar 20. Review.

8.

Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.

Tsapakidis K, Vlachostergios PJ, Voutsadakis IA, Befani CD, Patrikidou A, Hatzidaki E, Daliani DD, Moutzouris G, Liakos P, Papandreou CN.

Int J Urol. 2012 Jun;19(6):565-74. doi: 10.1111/j.1442-2042.2012.02967.x. Epub 2012 Feb 10.

9.

CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy.

Voutsadakis IA, Vlachostergios PJ, Daliani DD, Karasavvidou F, Kakkas G, Moutzouris G, Melekos MD, Papandreou CN.

Urol Int. 2012;88(2):158-64. doi: 10.1159/000335299. Epub 2012 Jan 28.

PMID:
22286396
10.

Lack of prognostic significance of p16 and p27 after radical prostatectomy in hormone-naïve prostate cancer.

Vlachostergios PJ, Karasavvidou F, Kakkas G, Kapatou K, Gioulbasanis I, Daliani DD, Moutzouris G, Papandreou CN.

J Negat Results Biomed. 2012 Jan 5;11(1):2. doi: 10.1186/1477-5751-11-2.

11.

Comparative study of spatial localization of HER-2 and CEP17 signals and of HER-2/CEP17 ratios, in "thin" and "thick" tissue sections.

Kouvaras E, Papandreou CN, Daliani DD, Athanasiadis A, Koukoulis GK.

Breast. 2012 Feb;21(1):34-9. doi: 10.1016/j.breast.2011.07.009. Epub 2011 Aug 19.

12.

p53 and cyclooxygenase-2 expression are directly associated with cyclin D1 expression in radical prostatectomy specimens of patients with hormone-naïve prostate cancer.

Vlachostergios PJ, Karasavvidou F, Patrikidou A, Voutsadakis IA, Kakkas G, Moutzouris G, Zintzaras E, Daliani DD, Melekos MD, Papandreou CN.

Pathol Oncol Res. 2012 Apr;18(2):245-52. doi: 10.1007/s12253-011-9435-2. Epub 2011 Jul 23.

13.

Inverse baseline expression pattern of the NEP/neuropeptides and NFκB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells.

Patrikidou A, Vlachostergios PJ, Voutsadakis IA, Hatzidaki E, Valeri RM, Destouni C, Apostolou E, Daliani D, Papandreou CN.

Cancer Cell Int. 2011 May 15;11(1):13. doi: 10.1186/1475-2867-11-13.

14.

Nonbacterial thrombotic (marantic) endocarditis in a patient with colorectal cancer.

Vlachostergios PJ, Daliani DD, Dimopoulos V, Patrikidou A, Voutsadakis IA, Papandreou CN.

Onkologie. 2010;33(8-9):456-9. doi: 10.1159/000317342. Epub 2010 Jul 7.

PMID:
20838062
15.

Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.

Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA.

J Clin Oncol. 2010 Aug 20;28(24):3851-7. doi: 10.1200/JCO.2010.29.5477. Epub 2010 Jul 12.

16.

The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 1: post-translational regulation.

Vlachostergios PJ, Patrikidou A, Daliani DD, Papandreou CN.

J Cell Mol Med. 2009 Sep;13(9B):3006-18. doi: 10.1111/j.1582-4934.2009.00824.x. Epub 2009 Jun 11. Review.

17.

The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 2: transcriptional regulation.

Vlachostergios PJ, Patrikidou A, Daliani DD, Papandreou CN.

J Cell Mol Med. 2009 Sep;13(9B):3019-31. doi: 10.1111/j.1582-4934.2009.00825.x. Epub 2009 Jun 11. Review.

18.

Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma.

Daliani DD, Tannir NM, Papandreou CN, Wang X, Swisher S, Wood CG, Swanson DA, Logothetis CJ, Jonasch E.

BJU Int. 2009 Aug;104(4):456-60. doi: 10.1111/j.1464-410X.2009.08490.x. Epub 2009 Mar 31.

19.

Prognostic significance of fascin expression in advanced poorly differentiated serous ovarian cancer.

Daponte A, Kostopoulou E, Papandreou CN, Daliani DD, Minas M, Koukoulis G, Messinis IE.

Anticancer Res. 2008 May-Jun;28(3B):1905-10. Erratum in: Anticancer Res. 2010 Jan;30(1):277. Papandreou, C N [added]; Daliani, D D [added].

20.

Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies.

Mao S, Daliani DD, Wang X, Thall PF, Do KA, Perez CA, Brown MA, Bouchillon K, Carter CM, Logothetis CJ, Kim J.

Prostate. 2007 Nov 1;67(15):1677-85.

PMID:
17879948
21.

CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma.

Faria SC, Ng CS, Hess KR, Phongkitkarun S, Szejnfeld J, Daliani D, Charnsangavej C.

AJR Am J Roentgenol. 2007 Aug;189(2):378-85.

PMID:
17646464
22.

Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma.

Pagliaro LC, Perez CA, Tu SM, Daliani DD.

Urol Oncol. 2006 Nov-Dec;24(6):487-91.

PMID:
17138128
23.

Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer.

Mathew P, Logothetis CJ, Dieringer PY, Chen I, Pagliaro LC, Bekele BN, Zhou X, Daliani DD.

Clin Genitourin Cancer. 2006 Sep;5(2):144-9.

PMID:
17026803
24.

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.

Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ.

J Clin Oncol. 2004 Jun 1;22(11):2108-21.

PMID:
15169797
25.

Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP).

Tu SM, Millikan RE, Pagliaro LC, Daliani D, Papandreou CN, Kim J, Chen DT, Williams DL, Logothetis CJ.

Urol Oncol. 2003 Sep-Oct;21(5):342-8.

PMID:
14670540
26.

Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.

Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM.

Clin Cancer Res. 2003 Jul;9(7):2587-97.

27.

Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience.

Siefker-Radtke AO, Gee J, Shen Y, Wen S, Daliani D, Millikan RE, Pisters LL.

J Urol. 2003 Apr;169(4):1295-8.

PMID:
12629346
28.

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.

Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB.

J Clin Oncol. 2003 Feb 15;21(4):679-89.

PMID:
12586806
29.

Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan.

Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J, Zonnenberg BA, Daliani DD, Schulman CC, Carducci MA.

J Urol. 2003 Mar;169(3):1143-9.

PMID:
12576870
30.

Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma.

Daliani DD, Assikis V, Tu SM, Papandreou CN, Pagliaro LC, Holtkamp T, Wang X, Thall PF, Logothetis CJ.

Cancer. 2003 Feb 1;97(3):561-7.

31.

A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.

Daliani DD, Papandreou CN, Thall PF, Wang X, Perez C, Oliva R, Pagliaro L, Amato R.

Cancer. 2002 Aug 15;95(4):758-65.

32.

Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.

Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ.

J Clin Oncol. 2002 Jul 15;20(14):3072-80.

PMID:
12118020
33.

Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma.

Pagliaro LC, Millikan RE, Tu SM, Williams D, Daliani D, Papandreou CN, Logothetis CJ.

J Clin Oncol. 2002 Jul 1;20(13):2965-70.

PMID:
12089226
34.

Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.

Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ.

Br J Cancer. 2002 May 20;86(10):1555-60.

35.

Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma.

Mian BM, Bhadkamkar N, Slaton JW, Pisters PW, Daliani D, Swanson DA, Pisters LL.

J Urol. 2002 Jan;167(1):65-70.

PMID:
11743277
36.

Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer.

Logothetis CJ, Wu KK, Finn LD, Daliani D, Figg W, Ghaddar H, Gutterman JU.

Clin Cancer Res. 2001 May;7(5):1198-203.

37.

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.

Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ.

Lancet. 2001 Feb 3;357(9253):336-41. Erratum in: Lancet 2001 Apr 14;357(9263):1210.

PMID:
11210994
38.

Development of angiogenesis inhibition as therapy for prostate cancer.

Daliani D.

Oncology (Williston Park). 2000 Dec;14(12 Suppl 13):21-3. Review.

39.

A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma.

Pagliaro L, Daliani D, Amato R, Tu SM, Jones D, Smith T, Logothetis C, Millikan R.

Cancer. 2000 Aug 1;89(3):615-8.

PMID:
10931461
40.

Cyclophosphamide and carboplatin and selective consolidation in advanced seminoma.

Amato RJ, Millikan R, Daliani D, Wood L, Logothetis C, Pollack A.

Clin Cancer Res. 2000 Jan;6(1):72-7.

41.

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G, et al.

J Clin Oncol. 1999 Nov;17(11):3461-7. Erratum in: J Clin Oncol 2000 Jul;18(13):2644. J Clin Oncol. 2007 Mar 20;25(9):1154. J Clin Oncol. 2013 May 1;31(13):1702.

PMID:
10550143
42.

Markers of androgen-independent progression of prostatic carcinoma.

Daliani D, Papandreou CN.

Semin Oncol. 1999 Aug;26(4):399-406. Review.

PMID:
10482182
43.

Tumor necrosis factor-alpha and interferon-gamma, but not HTLV-I tax, are likely factors in the epidermotropism of cutaneous T-cell lymphoma via induction of interferon-inducible protein-10.

Daliani D, Ulmer RA, Jackow C, Pugh W, Gansbacher B, Cabanillas F, Duvic M, Sarris AH.

Leuk Lymphoma. 1998 Apr;29(3-4):315-28. Review.

PMID:
9684929
44.

Primary ovarian non-Hodgkin's lymphoma: outcome after treatment with combination chemotherapy.

Dimopoulos MA, Daliani D, Pugh W, Gershenson D, Cabanillas F, Sarris AH.

Gynecol Oncol. 1997 Mar;64(3):446-50. Review.

PMID:
9062148
45.

Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas.

Sarris AH, Daliani D, Ulmer R, Crow M, Broxmeyer HE, Reiss M, Karasavvas N, Zelenetz AD, Pugh W, Cabanillas F, Deisseroth AB, Duvic M.

Clin Cancer Res. 1997 Feb;3(2):169-77.

46.

Interferon-inducible protein-10 and the pathogenesis of cutaneous T-cell lymphomas.

Sarris AH, Daliani D, Ulmer R, Crow M, Broxmeyer HE, Pugh W, Reiss M, Cabanillas F, Deisseroth AB, Duvic M.

Leuk Lymphoma. 1996 Dec;24(1-2):103-10.

PMID:
9049966
47.

Light-heavy chain deposition disease progressing to multiple myeloma.

Daliani D, Weber D, Alexanian R.

Am J Hematol. 1995 Dec;50(4):296-8.

PMID:
7485106
48.

Clinical problem-solving: costly errors.

Weber DM, Daliani D, Alexanian R.

N Engl J Med. 1995 Oct 19;333(16):1080; author reply 1081. No abstract available.

PMID:
7675063
49.

5-Fluorouracil, folinic acid and cisplatin in advanced colorectal cancer: a pilot study.

Tsavaris N, Tentas K, Bacoyiannis C, Katsikas M, Sakelaropoulos N, Kosmas C, Daliani D, Kosmidis P.

Anticancer Drugs. 1995 Aug;6(4):599-603.

PMID:
7579565
50.

Efficacy of ondansetron treatment with different timing schedules: a randomized double-blind study.

Tsavaris N, Mylonakis N, Bacoyiannis C, Karvounis N, Charalambidis G, Pagou M, Lioni A, Daliani D, Kosmidis P.

Oncology. 1995 Jul-Aug;52(4):315-8.

PMID:
7777246

Supplemental Content

Loading ...
Support Center